15 May 2021 : Database Analysis
H Long Terminal Repeat-Associating 2 (HHLA2) is a Biomarker of Advanced Stage Hepatocellular Carcinoma and Promotes Tumor Cell Development In Vitro
Min Luo1ABCE, Yao Xiong2BCE, Yan Lin1CD, Rong Liang1CD, Yongqiang Li1D, Lianying Ge3ADE*DOI: 10.12659/MSM.930215
Med Sci Monit 2021; 27:e930215
Figure 3 Hepatocellular carcinoma cell line screening. Hepatocellular carcinoma cell lines HepG2, SMMC-7721, and Huh-7 were screened for HHLA2 expression. HL-7702 cells were used as normal liver cells. (A) Relative HHLA2 mRNA levels based on qRT-PCR assay. * P<0.05. (B) Western blot analysis of HHLA2 protein. β-tubulin was used as an endogenous control. (C) HepG2 cells were transfected with lentivirus expressing 1 of 3 shRNAs targeting HHLA2 or a control shRNA, and HLLA2 knockdown efficiency was measured after 48 h by western blotting. HepG2+shRNA 1 caused the strongest knockdown (*** P<0.001). Actin was used as an endogenous control.